Josep Lluis Molinuevo

jlmoli@clinic.cat

Publicaciones destacadas

Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia

Autores:
Slot RER; Sikkes SAM; Berkhof J; Brodaty H; Buckley R;

(...)

; van der Flier WM Alzheimer's Disease Neuroimaging Initiative; DESCRIPA working group; INSIGHT-preAD study group; SCD-I working group.

Referencia: ALZHEIMER'S AND DEMENTIA.
CSF-ApoER2 fragments as a read-out of reelin signaling: Distinct patterns in sporadic and autosomal-dominant Alzheimer disease

Autores:
Lopez-Font I; Iborra-Lazaro G; Sánchez-Valle R; Molinuevo J; Cuchillo-Ibanez I;

Sáez-Valero J.

Referencia: CLINICA CHIMICA ACTA.
Two-Year Longitudinal Monitoring of Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity

Autores:
Jovicich J; Babiloni C; Ferrari C; Marizzoni M; Moretti DV;

(...)

Wiltfang J; Bordet R; Blin O; Frisoniand GB; and the PharmaCog Consortium.

Referencia: JOURNAL OF ALZHEIMER'S DISEASE 2019.
Plasma Aβ42 as Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study.

Autores:
Albani D; Marizzoni M; Ferrari C; Fusco F; Boeri L;

(...)

Bordet R; Blin O; Forloni G; Frisoni GB; Consortium P.

Referencia: JOURNAL OF ALZHEIMER'S DISEASE.
Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease-Data from three memory clinic studies

Autores:
Hu X; Teunissen CE; Spottke A; Heneka MT; Düzel E;

(...)

Coll-Padrós N; Rami L; Molinuevo JL; van der Flier WM; Jessen F.

Referencia: ALZHEIMER'S AND DEMENTIA 2019.
Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer's disease cerebrospinal fluid

Autores:
Lleó A; Núñez-Llaves R; Alcolea D; Chiva C; Balateu-Paños D;

(...)

Martínez-Lage P; Sánchez-Valle R; Sabidó E; Bayés À; Belbin O.

Referencia: MOLECULAR AND CELLULAR PROTEOMICS 2019.
Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease: Structural Brain Biomarkers.

Autores:
Marizzoni M; Ferrari C; Jovicich J; Albani D; Babiloni C;

(...)

Richardson JC; Bordet R; Blin O; Frisoni GB; PharmaCog Consortium.

Referencia: JOURNAL OF ALZHEIMER'S DISEASE.
Is there a difference in regional read [18F]flutemetamol amyloid patterns between end-of-life subjects and those with amnestic mild cognitive impairment?

Autores:
Farrar G; Molinuevo J; Zanette M;

Referencia: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING.
Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples

Autores:
Wolfsgruber S; Molinuevo JL; Wagner M; Teunissen CE; Rami L;

(...)

Wiltfang J; Sikkes SAM; van der Flier WM; Jessen F; Euro-SCD working group.

Referencia: 2019.
Alzheimer's disease is neither Alzheimer's clinical syndrome nor dementia

Autores:
Jagust W; Jack CR; Bennett DA; Blennow K; Haeberlein SB;

(...)

Rankin KP; Rowe CC; Scheltens P; Siemers E; Sperling R.

Referencia: ALZHEIMER'S AND DEMENTIA.

Proyectos destacados

CIBER de Fragilidad y Envejecimiento Saludable (CIBERFES)

Financiador: INSTITUTO DE SALUD CARLOS III

Duración: 01/01/2017
AMYPAD - Understanding the role of amyloid imaging biomarkers in the current and future diagnosis and management of patients across the spectrum of cognitive impairment (from pre-dementia to dementia)

Financiador: IMI (Programa Financiador competitivo); EUROPEAN UNION

Duración: 01/01/2016
EPAD - European Prevention of Alzheimer's Dementia, Innovative Medicines Initiative Joint Undertaking

Financiador: IMI (Programa Financiador competitivo)

Duración: 01/01/2015
Meditaging

Financiador: HORIZON2020 (Programa Financiador competitivo)

Duración: 01/01/2015
AETIONOMY - Organising mechanistic knowledge about neurodegenerative diseases for the improvement of drug development and therapy (AETIONOMY); Innovative Medicines Initiative

Duración: 01/01/2014

Josep Lluis Molinuevo

Publicaciones destacadas

Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer's disease cerebrospinal fluid

Proyectos destacados

CIBER de Fragilidad y Envejecimiento Saludable (CIBERFES)

AMYPAD - Understanding the role of amyloid imaging biomarkers in the current and future diagnosis and management of patients across the spectrum of cognitive impairment (from pre-dementia to dementia)

EPAD - European Prevention of Alzheimer's Dementia, Innovative Medicines Initiative Joint Undertaking

Meditaging

AETIONOMY - Organising mechanistic knowledge about neurodegenerative diseases for the improvement of drug development and therapy (AETIONOMY); Innovative Medicines Initiative

Suscríbete a la Newsletter del Clínic